Status:
COMPLETED
Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
Lead Sponsor:
Karolinska University Hospital
Collaborating Sponsors:
Schering Nordiska AB
Conditions:
B-CLL
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).
Eligibility Criteria
Inclusion
- B-CLL that has failed fludarabine
Exclusion
- Performance status grade 3
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00162851
Start Date
April 1 2003
End Date
July 1 2006
Last Update
July 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Hematology, Karolinska University Hospital
Stockholm, Sweden, SE-171 76